With a record of accomplishment encompassing more than 20 years in early drug discovery, Evotec today has a globally leading position in first-in-class drug discovery research and development with >2,600 employees at 14 sites in France, Germany, Italy, Switzerland, UK, and the USA.
In its operating segment EVT Execute, Evotec offers its customers services along the complete value chain in drug discovery from target identification to IND submission and CMC.
In its operating segment EVT Innovate, Evotec focuses on accelerating innovation through various collaborative models either with Academia, other biotech companies, Pharma companies or even a combination of those in so-called academic BRIDGE alliances. In addition to its equity strategy, Evotec is willing to take on different angles to bring forward new innovative approaches, e.g. by spinning off valuable platforms and keeping an equity stake or participating in financing rounds and company formations.